Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAV Regimen (Mitoxantrone Liposome, Cytarabine, Venetoclax) in R/R AML
NCT06621212Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Composite Complete Remission Rate. Started Jul 2024; status: recruiting.
02
Drugs
mitoxantrone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06621212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621212.